Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect

Histology and Histopathology

Volumn 27, Issue 2, 2012, Pages 133-140

  Kuroda, Naoto ^a   Mikami, Shuji ^b   Pan, Chin Chen ^c   Cohen, Ronald J ^d   Hes, Ondrej ^d   Michal, Michal ^d   Nagashima, Yoji ^e   Tanaka, Yukichi ^f   Inoue, Keiji ^g   Shuin, Taro ^g   Lee, Gang Hong ^h  

^a KOCHI RED CROSS HOSPITAL   (Japan)

^b KEIO UNIVERSITY HOSPITAL   (Japan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHARLES UNIVERSITY   (Czech Republic)

^e YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^g Departments of Urology   (Japan)

^h KOCHI UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; TFE3; Xp11.2 RCC

Indexed keywords

BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; ONCOPROTEIN; TFE3 PROTEIN, HUMAN;

GENE FUSION; GENE TRANSLOCATION; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; PATHOLOGY; REVIEW; X CHROMOSOME;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, X; GENE FUSION; HUMANS; KIDNEY NEOPLASMS; ONCOGENE PROTEINS, FUSION; TRANSLOCATION, GENETIC;

EID: 84863407430     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Argani P. and Ladanyi M. (2004). Renal carcinomas associated with Xp11.2 translocations/TFE3 gene fusions. In: Pathology and genetics. Tumours of the urinary system and male genital organs. Chapter 1. Eble J.N., Sauter G., Epstein J.I. and Sesterhenn I.A. (eds). IRAC Press. Lyon. pp 37-38.
2. Argani P., Antonescu C.R., Illei P.B., Lui M.Y., Timmons C.F., Newbury R., Reuter V.E., Garvin A.V., Perez-Atayde A.R., Fletcher J.A., Beckwith J.B., Bridge J.A. and Ladanyi M. (2001). Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: A distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am. J. Pathol. 159, 179-192.
3. Argani P., Antonescu C.R., Couturier J., Fournet J-C., Sciot R., Debiec-Rychter M., Hutchinson B., Reuter V.E., Boccon-Gibod L., Timmons C., Hafez N. and Ladanyi M. (2002). PRCC-TFE3 renal carcinomas: Morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am. J. Surg. Pathol. 26, 1553-1566.
4. Argani P., Lal P., Hutchinson B., Lui M.Y., Reuter V.E. and Ladanyi M. (2003a). Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am. J. Surg. Pathol. 27, 750-761.
5. Argani P., Lui M.Y., Couturier J., Bouvier R., Fournet J-C. and Ladanyi M. (2003b). A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene 22, 5374-5378.
6. Argani P., Lae M., Hutchinson B., Reuter V.E., Collins M.H., Perentesis J., Tomaszewaki J.E., Brook J.S.J., Ac G., Bridge J.A., Vargas S.O., Davis I.J., Fisher D.E. and Ladanyi M. (2005). Renal carcinomas with t(6;11)(p21;q12): Clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am. J. Surg. Pathol. 29, 230-241.
7. Argani P., Lae M., Ballard E.T., Amin M., Manivel C., Hutchinson B., Reuter V.E. and Ladanyi M. (2006). Translocation carcinomas of the kidney after chemotherapy in childhood. J. Clin. Oncol. 24, 1529-1533.
8. Argani P., Olgac S., Tickoo S.K., Goldfischer M., Moch H., Chan D.Y., Eble J.N., Bonsib J.N., Jimeno M., Lloreta J., Billis A., Hicks J., De Marzo A.M., Reuter V.E. and Ladanyi M. (2007). Xp11 translocation renal cell carcinoma in adults: Expanded clinical, pathologic, and genetic spectrum. Am. J. Surg. Pathol. 31, 1149-1160.
9. Argani P., Aulmann S., Karanjawala Z., Fraser R.B., Ladanyi M. and Rodriguez M.M. (2009). Melanotic Xp11 translocation renal cancers: A distinctive neoplasm with overlapping features of PEComa, carcinoma and melanoma. Am. J. Surg. Pathol. 33, 609-619.
10. Argani P., Aulmann S., Illei P.B., Netto G.J., Ro J., Cho H.Y., Dogan S., Ladanyi M., Martignoni G., Goldblum J.R. and Weiss S.W. (2010a). A distinctive subset of PEComas harbors TFE3 gene fusions. Am. J. Surg. Pathol. 34, 1395-1406.
11. Argani P., Hicks J., De Marzo A.M., Albadine R., Illei P.B., Ladanyi M., Reuter V.E. and Netto G.J. (2010b). Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am. J. Surg. Pathol. 34, 1295-1303.
12. Armah H.B., Parwani A.V., Surti U. and Bastacky S.I. (2009). Xp11.2 translocation renal cell carcinoma occurring during pregnancy with a novel translocation involving chromosome 19: A case report with review of the literature. Diagn. Pathol. 4, 15.
13. Aydin H., Magi-Galluzzi C.M., Lane B.R., Sercia L., Lopez J.I., Rini B.I. and Zhou M. (2009). Renal angiomyolipoma: Clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am. J. Surg. Pathol. 33. 289-297.
14. Bruder E., Passera O., Harms D., Leuschner I., Ladanyi M., Argani P., Eble J.N., Struckmann K., Schrraml P. and Moch H. (2004). Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am. J. Surg. Pathol. 28, 1117-1132.
15. Camparo P., Vasiliu V., Molinie V., Coutturier J., Dykema K.J., Petillo D., Furge K.A., Comperat E.M., Lae M., Bouvier R., Boccon-Gibod L., Denoux Y., Ferlicot S., Forest E., Fromont G., Hintzy M.C., Laghouuati M., Sibony M., Tucker M.L., Weber N., The B. T. and Viellefond A. (2008). Renal translocation carcinomas: Clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am. J. Surg. Pathol. 35, 656-670.
16. Choueiri T.K., Mosquera J.M. and Hirsch M.S. (2009). A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin. Genitourinary Cancer 7, E93-94.
17. Choueiri T.K., Lim Z.D., Hirsh M.S., Tamboli P., Jonasch E., McDermott D.F., Cin P.D., Corn P., Vaishampayan U., Heng D.Y.C. and Tannir N.M. (2010). Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 116, 5219-5225.
18. Clark J., Lu Y-J., Sidhar S.K., Parker C., Gill S., Smedley D., Hamoudi R., Linehan W.M., Shipley J. and Cooper C.S. (1997). Fusion of splicing factor genes PSF and NonO(p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 15, 2233-2239.
19. Dal Cin P., Stas M., Sciot R., De Wever L., van Damme B. and van den Berghe H. (1998). Translocation (X;1) reveals metastasis 31 years after renal cell carcinoma. Cancer Genet. Cytogenet. 101, 58-61.
20. de Jong B., Molenaar I.M., Leeuw J.A., Idunberg V.J. and Oosterhuis J.W. (1986). Cytogenetics of a renal adenocarcinoma in a 2-year-old child. Cancer Genet. Cytogenet. 21, 165-169.
21. Desangles F., Camparo P., Fouet C., Houlgatte A. and Arborio M. (1999). Translocation (X;1) associated with nonpapillary carcinoma in a young woman: a new definition for an Xp11.2 RCC subtype. Cancer Genet. Cytogenet. 113, 141-144.
22. Dijkhuizen T., van den Berg E., Wilbrink M., Weterman M., Geurts van Kessel A., Storkel S., Folkers R.P., Braam A. and de Jong B. (1995). Distinct Xp11.2 breakpoints in two renal cell carcinomas exhibiting X; autosome translocations. Gene Chromosome Cancer 14, 43-50.
23. Geller J.I., Argani P., Adeniran A., Hampton E., De Marzo A., Hicks J. and Collins M.H. (2008). Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer 112, 1607-1616.
24. Gobbo S., Eble J.N., Grignon D.J., Martignoni G., MacLennan G.T., Shah R.B., Zhang S., Brunelli M. and Cheng L. (2008). Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am. J. Surg. Pathol. 32, 1239-1245.
25. Gupta R., Balzer B., Picken M., Osunkoya A.O., Shet T., Alsabeh R., Luthringer D., Paner G.P. and Amin M.B. (2009). Diagnostic implications of transcription factor PAX2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am. J. Surg. Pathol. 33, 241-247.
26. Heimann P., Housni H.E., Ogur G., Weterman M.A.J., Pettey E.M. and Vassart G. (2001). Fusion of a novel gene, RCC 17, to the TFE3 gene in t(X;17)(p11.2;q25.3)-bearing papillary renal cell carcinoma. Cancer Res. 61, 4130-4135.
27. Kardas I., Denis A., Babinska M., Gronwald J., Podolski J., Zajaczek S., Kram A., Lubinski J. and Limon J. (1998). Translocation (X;1)((p11.2;q21) in a papillary renal cell carcinoma in a 14-year-old girl. Cancer Genet. Cytogenet. 101, 159-161.
28. Komai Y., Fujiwara M., Fujii Y., Mukai H., Yonese J., Kawakami S., Yamamoto S., Migita T., Ishikawa Y., Kurata M., Nakamura T. and Fukui I. (2009). Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin. Cancer Res. 15, 1170-1176.
29. Kovacs G., Szucs S., De Riese W. and Baumgartel H. (1987). Specific chromosome aberration in human renal cell carcinoma. Int. J. Cancer 40, 171-178.
30. Kuroda N., Tamura M., Tanaka Y., Hes O., Michal M., Inoue K., Ohara M., Mizuno K. and Lee G.H. (2009). Adult-onset renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusion with smooth muscle stroma and abnormal vessels. Pathol. Int. 59, 486-491.
31. Kuroda N., Katto K., Tanaka Y., Yamaguchi T., Inoue K., Ohara M., Mizuno K., Hes O., Michal M. and Lee G.H. (2010). Diagnostic pitfall on the histological spectrum of adult-onset renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions. Med. Mol. Morphol. 43, 86-90.
32. Malouf G.G., Camparo P., Oudard S., Schleiermacher G., Theodore C., Rustine A., Dutcher J., Billemont B., Rixe O., Bompas E., Guillot A., Boccon-Gibod L., Coutier J., Molinie V. and Escudier B. (2010). Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the juvenile RCC network. Ann. Oncol 21, 1834-1838.
33. Mansouri D., Dimet S., Couanet D., Terrier-Lacombe M-J., Vasiliu V., Khalifa C., Suciu V. and Viehl P. (2006). Renal cell carcinoma with an Xp11.2 translocation in a 16-year-old girl: A case report with cytologic features. Diagn. Cytopathol. 34, 757-760.
34. Martignoni G., Pea M., Gobbo S., Brunelli M., Bonetti F., Segata D., Pan C.C., Netto G., Doglioni C., Hes O., Argani P. and Chilosi M. (2009). Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal cell carcinomas from other renal carcinomas. Mod. Pathol. 22, 1016-1022.
35. Medendorp K., van Groningen J.J.M., Schepens M., Vreede L., Thijssen J., Schoenmakers E.F.P.M., van den Hurk W.H., Geurts van Kessel A. and Kuiper R.P. (2007). Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas. Cytogenet. Genome Res. 118, 157-165.
36. Meloni A.M., Sanberg A.A., Pontes J.E. and Dobbs R.M. (1992). Translocation (X;11)(p11.2;q21): A subtype of renal adenocarcinoma. Cancer Genet. Cytogenet. 63, 100-101.
37. Meloni A.M., Dobbs R.M., Pontes J.E. and Sanberg A.A. (1993). Translocation (X;11) in papillary renal cell carcinoma: A new cytogenetic subtype. Cancer Genet. Cytogenet. 65, 1-6.
38. Meyer P.N., Clark J.I., Flanigan R.C. and Pickern M.M. (2007). Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Am. J. Clin. Pathol. 128, 70-79.
39. Mir C., Trilla E., De Torres I.M., Panizo A., Zlotta A.R., Rhijn B.V. and Morete J. (2011). Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome. BJU Int. 108, E71-E76.
40. Nouh M.A.A.M., Kuroda N., Yamashita M., Hayashida Y., Yano T., Minakuchi J., Taniguchi S., Nomura I., Inui M., Sugimoto M. and Kakehi Y. (2010). Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis. BJU Int. 105, 620-627.
41. Ohjimi Y., Iwasaki H., Ishiguro M., Hara H., Ohgami A., Kikuchi M. and Kaneko Y. (1993). Deletion (X)(p11): an other case of renal adenocarcinoma with involvement of Xp11. Cancer Genet Cytogenet. 70, 77-78.
42. Onder A.M., Teomete U., Argani P., Toledano S., Zilleruelo G. and Rodriguez M.M. (2006). PRCC-TFE3 renal cell carcinoma in a boy with a history of contralateral mesoblastic nephroma. Pediatr. Nephrol. 21, 1471-1475.
43. Parikh J., Coleman T., Messias N. and Brown J. (2009). Temsirolimus in the treatment of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion proteins: a case report and review of the literature. Rare tumors 1, 164-166.
44. Perot C., Bougaran J., Boccon Gibod L., Storkel S., Leverger G., van den Akker J., Taillemite J.L. and Couturier J. (1999). Two new cases of papillary renal cell carcinoma with t(X;11)(p11;q21) in females. Cancer Genet. Cytogenet. 59, 2021-2050.
45. Petersson F., Vanecek T., Michal M., Martignoni G., Brunelli M., Spagnolo D., Kuroda N., Yang X., Alvarado-Cabrero I., Hora M. and Hes O. (2011). Renal translocation t(6;11) carcinoma: A study on 5 cases using histomorphology, immunohistochemistry, ultrastructure and molecular genetic techniques. Mod. Pathol. 24, 217A.
46. Prasad S.R., Humphrey P.A., Catena J.R., Narra V.R., Srigley J.R., Cortez A.D., Dalrymple N.C. and Chintapalli K.N. (2006). Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Ragiographics 26, 1795-1810.
47. Ramphal R., Pappo A., Zielenska M., Grant R. and Ngan B.Y. (2006). Pediatric renal cell carcinoma: Clinical, pathologic, and molecular abnormalities associated with the numbers of the MiT transcription factor family. Am. J. Clin. Pathol. 126, 349-364.
48. Sagara Y., Miyata Y., Namata K., Abe K., Eguchi J., Hayashi T., Sakai H., Kanda S. and Kanetake H. (2009). TFE3-renal carcinoma in an adult patient: A case with strong expression of phosphatase hepatocyte growth factor (HGFR) Met. Pathol. Res. Pract. 205, 57-61.
49. Schinstine M., Filie A.C., Torres-Cabala C., Abati A., Linehan W.M. and Merino M. (2006). Fine-needle aspiration of a Xp11.2 translocations/TFE3 fusion renal cell carcinoma metastatic to the lung: Report of a case and review of the literature. Diagn. Cytopathol. 34, 751-756.
50. Shipley J.M., Birdsall S., Clark J., Crew J., Gill S., Linehan M., Gnarra J., Fisher S., Craig I.W. and Cooper C.S. (1995). Mapping the X chromosome breakpoint in two papillary renal cell carcinoma cell lines with a t(X;1)(p11.2;q21.2) and the first report of a female case. Cytogenet. Cell Genet. 71, 280-284.
51. Sidhar S.K., Clark J., Gill S., Hamoudi R., Crew A.J., Gwilliam R., Ross M., Linehan W.M., Birdsall S., Shipley J. and Cooper C.S. (1996). The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum. Mol. Genet. 5, 1333-1338.
52. Suzigan S., Drut R., Faria P., Argani P., De Marzo A.M., Barbosa R.N., Mello Denadai E.R., Martins-Filho J., Martucci R.C. and Bauab T. Jr. (2007). Xp11.2 translocation carcinoma of the kidney presenting with multilocular cystic renal cell carcinoma-like features. Int. J. Surg. Pathol. 15:199-203.
53. Tanaka M., Kato K., Gomi K., Matsumoto M., Kudo H., Shinkai M., Ohama Y., Kigasawa H. and Tanaka Y. (2009). Perivascular epithelioid cell tumor with SFPQ/PSF-TFE3 gene fusion in a patient with advanced neuroblastoma. Am. J. Surg. Pathol. 33, 1416-1420.
54. Tomlinson G.E., Nisen P.D., Timmons C.F. and Schneider N.R. (1991). Cytogenetics of a renal cell carcinoma in a 17-month-old child: Evidence for Xp11.2 as a recurring breakpoint. Cancer Genet. Cytogenet. 57, 11-17.
55. Tonk V., Wilson K.S., Timmons C.F., Schneider N.R. and Tomlinson G.E. (1995). Renal cell carcinoma with translocation (X;1). Further evidence for a cytogenetically defined subtype. Cancer Genet. Cytogenet. 81, 72-75.
56. Tsuda M., Davis I.J., Argani P., Shukla N., McGill G.G., Nagai M., Saito T., Lae M., Fisher M.L. and Ladanyi M. (2007). TFE3 fusion activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 67, 919-929.
57. Weterman M.A.J., Wilbrink M., Janssen I., Janssen H.A.P., van den Berg E., Fisher S.E., Craig I. and Geurts van Kessel A. (1996a). Molecular cloning of the papillary renal cell carcinoma-associated translocation (X;1)(p11;q21) breakpoint. Cytogenet. Cell Genet. 75, 2-6.
58. Weterman M., Wilbrink M., Dijkhuizen T., van den Berg E. and Geurts van Kessel A. (1996b). Fine mapping of the 1q21 breakpoint of the papillary renal cell carcinoma-associated (X;1) translocation. Hum. Genet. 98, 16-21.
59. Weterman M.A.J., Wilbrink M. and Geurts van Kessel A. (1996c). Fusion of the transcription factor TFE3 gene to a novel gene: PRCC, in the t(X;1)(p11;q21)-positive papillary renal cell carcinoma. Proc. Acad. Sci. USA 93, 15294-15298.
60. Yamaguchi T., Kuroda N., Imamura Y., Hes O., Kawada T. and Nakayama K. (2009). Imprint cytologic features in renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in an adult. Acta Cytol.53, 693-697.
61. Yan B.C., Mackinnon A.G, and Al-Ahmadie H.A. (2009). Recent developments in the pathology of renal tumors: Morphology and molecular characteristics of select entities. Arch. Pathol. Lab. Med. 133, 1026-1032.
62. Zhong M., Angelo P.D., Osborne L., Keane-Tarchichi M., Goldfischer M., Edelmann L., Yang Y., Linehan M., Merino M.J., Aisner S. and Hameed M. (2010). Dual-color, break-apart FISH assay on paraffinembedded tissues as an adjunct to diagnosis of Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma. Am. J. Surg. Pathol. 34, 757-766.